A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients
| Autor: | H-T. Chiang, K-M. Chu, K-H. Shu, P.y-A. Ding |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Ambulatory blood pressure Urology Angiotensin-Converting Enzyme Inhibitors Blood Pressure Placebo Essential hypertension Benzoates Double-Blind Method Internal medicine Humans Medicine Telmisartan Antihypertensive Agents Aged business.industry General Medicine Blood Pressure Monitoring Ambulatory Middle Aged medicine.disease Treatment Outcome Endocrinology Losartan Blood pressure Tolerability Hypertension Ambulatory Benzimidazoles Female business Angiotensin II Type 1 Receptor Blockers medicine.drug |
| Zdroj: | International Journal of Clinical Practice. 58:16-22 |
| ISSN: | 1368-5031 |
| DOI: | 10.1111/j.1742-1241.2004.00405.x |
| Popis: | Summary Ambulatory blood pressure monitoring (ABPM) was used to compare the efficacy and tolerability of once-daily telmisartan 40 mg and once-daily losartan 50 mg in Taiwanese patients with mild-to-moderate essential hypertension in a randomised, double-blind, double-dummy, parallel-group study. The initial 2-week placebo run-in phase was followed by randomisation to treatment with telmisartan 40 mg (n = 31) or losartan 50 mg (n = 30) for 6 weeks. The reduction in 18- to 24-h mean (SE) ambulatory diastolic blood pressure (DBP) from baseline was significantly greater with telmisartan 40 mg (−12.1 ± 1.6 mmHg, p = 0.036) than with losartan 50 mg (−7.0 ± 1.8 mmHg). The reduction in 18- to 24-h mean (SE) ambulatory systolic blood pressure (SBP) from baseline was also greater with telmisartan 40 mg (−16.0 ± 2.4 mmHg) than with losartan 50 mg (−11.8 ± 2.7 mmHg), but did not achieve statistical significance. Telmisartan was well tolerated; no serious adverse events occurred. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|